📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-06 18:45
298 analysed today
FollowTelegram
298
Today
149,699
All-time analysed
42,924
Positive
6,662
Negative
91,432
Neutral
8,613
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
16 announcements match the current filters (relevance ≥ 5).
Chandan Healthcare Secures ₹5.22 Cr Loan from ICICI Bank for 128-Slice CT Scanner
Chandan Healthcare Limited has been sanctioned a Medical Equipment Loan of ₹5.22 crore by ICICI Bank Limited on October 05, 2026. The facility will fund 90% of the purchase cost of a 128-slice CT scanner, valued at ₹5.80 crore, with the company providing the remaining 10% margin. The loan carries an interest rate of 8.75% p.a. over a 60-month tenure, including a 60-day moratorium. Relative to TTM revenue of ₹289 crore, this ₹5.80 crore capex represents ~2.0% of annual turnover.
Confidence: HIGH
What changedChandan Healthcare has secured and accepted a ₹5.22 crore bank loan to finance a new high-end CT scanner.
Why it mattersThe new equipment expands the company's diagnostic radiology capacity in line with its strategy to increase high-margin super-specialty tests.
Sanctioned Loan Amount: ₹5,22,00,000Asset Cost: ₹5,80,00,000Rate of Interest: 8.75% p.a.Tenure: 60 monthsCapex vs TTM Revenue: ~2.0%
📅 Short termMarginal short-term impact on cash flows as the 10% margin is deployed; operations will await delivery and commissioning of the scanner.
📈 Long termSupports incremental high-margin radiology revenue and aligns with the company's focus on advancing super-specialty diagnostics.
⚠ Risk flags
- Utilization risk if scanner patient volumes ramp up slower than anticipated
- Debt servicing obligations over the 5-year loan tenure
Key Highlights
Loan facility of ₹5.22 crore sanctioned by ICICI Bank Limited
Asset cost stands at ₹5.80 crore for one 128-slice CT scanner (90% debt-funded)
Interest rate fixed at 8.75% p.a. with a 60-month tenure including a 60-day moratorium
Company to fund 10% margin alongside hypothecation of the acquired asset
👀 What to Watch
Monitor the installation timeline and operational ramp-up of the CT scanner to see its contribution to super-specialty radiology test volumes in upcoming quarters.
Chandan Healthcare Raises ₹15.21 Cr via Allotment of 6.5 Lakh Shares on Warrant Conversion
Chandan Healthcare Limited approved the allotment of 6,50,000 equity shares of face value ₹10 each at an issue price of ₹234 per share (including a premium of ₹224 per share), aggregating to ₹15.21 crore. The allotment follows the conversion of fully convertible warrants issued on a preferential basis to non-promoter entities Negen Capital Services and Negen Undiscovered Value Fund. Post-allotment, the company's paid-up share capital increased from ₹25.05 crore (2,50,52,062 shares) to ₹25.70 crore (2,57,02,062 shares). A total of 32,00,002 warrants remain outstanding for future conversion.
Confidence: HIGH
What changedChandan Healthcare converted 6,50,000 preferential warrants into equity shares, raising ₹15.21 crore in total equity capital.
Why it mattersThe infusion strengthens the balance sheet with fresh equity and expands the public institutional shareholder base, while slightly diluting existing equity base by ~2.53%.
Shares allotted: 6,50,000Issue price per share: ₹234Total consideration: ₹15,21,00,000Post-allotment paid-up capital: ₹25,70,20,620Remaining warrants outstanding: 32,00,002
📅 Short termNeutral to mildly positive as the company formalizes the listing of newly allotted shares, which are subject to statutory lock-in periods.
📈 Long termSupports growth capital needs for diagnostic footprint expansion, although further dilution remains ahead with 32 lakh warrants still unexercised.
⚠ Risk flags
- Equity dilution of ~2.53% from this tranche, with potential further dilution from 32,00,002 outstanding warrants
Key Highlights
Allotment of 6,50,000 equity shares at an issue price of ₹234 per share
Total consideration received for the shares is ₹15,21,00,000 (with balance ₹11.41 crore received now)
Paid-up equity share capital increases from ₹25.05 crore to ₹25.70 crore, expanding share count to 2,57,02,062
Allottees Negen Undiscovered Value Fund and Negen Capital Services now hold 1.56% and 0.97% equity stake, respectively
32,00,002 warrants remain outstanding for conversion
👀 What to Watch
Track the receipt of listing and trading approvals from the exchange within 20 days, and watch for the deployment of funds toward planned franchise and lab network expansions.
Chandan Healthcare Acquires 2 Units of Ansh Diagnostics & Health Care in Ghaziabad
Chandan Healthcare Limited has entered into an agreement on September 25, 2026, to acquire two units of Ansh Diagnostics & Health Care situated in Ghaziabad, Uttar Pradesh. The acquired target operates pathology and advanced radiology facilities, including CT and MRI services. Financial details such as acquisition cost, turnover, and consideration were not disclosed in the filing. The transaction is at arm's length with no promoter group interest, aimed at expanding Chandan's diagnostic footprint in the National Capital Region.
Confidence: MEDIUM
What changedChandan Healthcare has acquired two operating diagnostic centers of Ansh Diagnostics & Health Care in Ghaziabad, UP.
Why it mattersExpands Chandan's presence into the Ghaziabad/NCR market and bolsters higher-margin radiology offerings like CT and MRI.
Units acquired: 2Agreement date: 25-09-2026Acquisition cost: not disclosedTarget revenue: not disclosed
📅 Short termIntegration of the two centers should commence immediately; sentiment is mildly positive given geographic expansion, though lack of financial details limits immediate re-rating.
📈 Long termSupports the company's objective to expand its diagnostic footprint in North India by adding advanced CT and MRI testing capabilities.
⚠ Risk flags
- Key transaction terms including deal value and target financials are not disclosed
- Post-acquisition integration risk in a competitive diagnostic market
Key Highlights
Acquired 2 operational units of Ansh Diagnostics located at Gyan Khand 2 (Indirapuram) and Raj Hansh Tower (Ahinsha Khand) in Ghaziabad
Target adds pathology and radiology capabilities, specifically CT and MRI infrastructure
Agreement executed on September 25, 2026, with zero governmental or regulatory approvals required
Acquisition cost and revenue contribution were not disclosed in the disclosure
👀 What to Watch
Monitor upcoming quarterly disclosures to assess the acquisition consideration paid, revenue accretion, and margin impact from these two Ghaziabad units.
Chandan Healthcare Scales Franchise Network to 500+ Centres; Targets 1,000 by FY27-End
Chandan Healthcare announced that its diagnostic franchise network has crossed 500 operational centres, bringing its total diagnostic network to 568+ centres as of September 15, 2026. The franchise model operates on zero capex from the company, with franchise partners covering local operating expenses while Chandan provides diagnostic processing and branding. Management plans to double the franchise count to 1,000 centres by FY27-end and subsequently expand to 3,000 centres over the following two years. Around 80% of current franchise centres are in Uttar Pradesh, with future expansion targeting a pan-India footprint.
Confidence: HIGH
What changedChandan Healthcare reached a milestone of 500+ operational franchise collection centres and outlined targets to expand to 1,000 by FY27-end and 3,000 over the next two years.
Why it mattersThe asset-light franchise model adds high-margin sample volumes to existing owned labs without requiring capital deployment, boosting capacity utilization and geographical reach.
Operational Franchise Centres: 500+Total Diagnostic Network: 568+ centresFY27-End Franchise Target: 1,000 centresLong-term Franchise Target: 3,000 centresFY26 Consolidated Total Income: ₹280.67 CrFY26 Consolidated PAT: ₹27.06 Cr
📅 Short termPositive sentiment driven by achieving the 500-centre milestone and visibility on asset-light network scaling.
📈 Long termA successful scale-up to 3,000 collection centres could significantly drive operating leverage across its 2 Central Reference Labs and 25 standalone labs, aiding pan-India expansion beyond Uttar Pradesh.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Geographic concentration with ~80% of network in Uttar Pradesh
- Intense competitive discounting from established national diagnostic chains like Dr. Lal PathLabs
- Execution risks in scaling quality and sample turnaround times across new geographies
Key Highlights
Franchise network reached 500+ operational centres, expanding total diagnostic footprint to 568+ centres as of September 15, 2026
Targets doubling franchise centres to 1,000 by FY27-end and scaling to 3,000 centres over the subsequent two years
Zero capex deployment from Chandan Healthcare as franchise partners bear local capex and operating expenses
Approximately 80% of existing franchise network currently concentrated in Uttar Pradesh
FY26 reported Consolidated Total Income of ₹280.67 Cr, EBITDA of ₹56.84 Cr, and PAT of ₹27.06 Cr
👀 What to Watch
Monitor upcoming quarterly results (such as Q2 FY27) to assess whether sample volumes from the 500+ franchise collection points translate into improved lab utilization and operating leverage.
Chandan Healthcare Allots 5.99 Lakh Shares on Warrant Conversion Worth ₹14.04 Cr
Chandan Healthcare has approved the allotment of 5,99,998 equity shares following the conversion of fully convertible warrants issued on a preferential basis. The allotment was executed at an issue price of ₹234 per share (including ₹224 premium), aggregating to ₹14.04 crore. Strategic partner Jeena Sikho Lifecare was allotted 4,50,000 shares, taking a 1.80% post-allotment equity stake. Following this conversion, the company's paid-up equity share capital increased from ₹24.45 crore to ₹25.05 crore, while 38,50,002 warrants remain outstanding.
Confidence: HIGH
What changedChandan Healthcare converted 5,99,998 preferential warrants into equity shares, raising ₹10.53 crore in balance consideration.
Why it mattersThe warrant exercise brings equity capital into the company and solidifies the equity alignment with strategic partner Jeena Sikho Lifecare.
Total consideration: ₹14,03,99,532.00Issue price per share: ₹234Shares allotted: 5,99,998Jeena Sikho post-allotment stake: 1.7963%Warrants outstanding: 38,50,002
📅 Short termReceipt of listing and trading approvals for the 5.99 lakh equity shares within 20 days.
📈 Long termDrives strategic alignment with Jeena Sikho Lifecare to support pan-India expansion and patient footfall in diagnostics.
⚠ Risk flags
- Equity dilution of ~2.45% from this tranche, with an additional 38.5 lakh warrants remaining outstanding until August 2027
Key Highlights
5,99,998 equity shares allotted at ₹234 per share (₹10 face value + ₹224 premium)
Total consideration received is ₹14,03,99,532.00, including ₹10.53 crore balance payment received now
Jeena Sikho Lifecare converted 4,50,000 warrants, acquiring a 1.7963% stake post-allotment
Paid-up equity share capital increases from 2,44,52,064 to 2,50,52,062 equity shares
38,50,002 total warrants remain outstanding across all preferential allottees
👀 What to Watch
Track the listing and trading approval of the newly allotted 5,99,998 equity shares on the exchange, and monitor further warrant conversion triggers before the August 3, 2027 expiration.
Chandan Healthcare Reallocates ₹50 Cr Warrant Proceeds to Build New Diagnostic Labs
Chandan Healthcare's Board has recommended reallocating ₹50.00 crore of unutilised proceeds from its 44,50,000 preferential convertible warrants. The funds, originally earmarked for acquiring existing diagnostic units and assets, will now be used to set up new diagnostic laboratories and comprehensive diagnostic centres. The Board also recommended the appointment of retired SGST Additional Commissioner Sanjay Srivastava as an Independent Director for a five-year term ending 29 September 2031. Both proposals are subject to shareholder approval at the Annual General Meeting on 30 September 2026.
Confidence: HIGH
What changedChandan Healthcare changed the planned use of ₹50 crore unutilised warrant proceeds from inorganic acquisitions to building new diagnostic labs and centres directly.
Why it mattersThe pivot shifts the company's capital deployment strategy toward organic network expansion, altering the pace and margin profile of new capacity additions.
Reallocated proceeds: Rs. 50,00,00,000Convertible warrants count: 44,50,000Cost auditor remuneration: Rs. 1,25,000AGM date: 30 September 2026
📅 Short termNeutral as the change requires shareholder approval on 30 September 2026 before funds can be deployed into ground-level lab rollouts.
📈 Long termSetting up owned greenfield labs may offer better long-term unit economics and quality control compared to acquiring older diagnostic centres, but involves longer gestation periods.
⚠ Risk flags
- Execution and gestation risk associated with setting up greenfield diagnostic labs compared to plug-and-play acquisitions
- Shareholder approval pending for the object variation at the AGM
Key Highlights
₹50,00,00,000 (₹50 Cr) in unutilised warrant proceeds reallocated to setting up new diagnostic labs and centres
Shift in strategy from inorganic acquisitions of existing units to organic setup of comprehensive centres
Appointment of Mr. Sanjay Srivastava as Independent Director for a 5-year term from 30 September 2026 to 29 September 2031
Shareholder approval to be sought via Special Resolution at the AGM on 30 September 2026
👀 What to Watch
Track shareholder approval at the upcoming AGM on 30 September 2026 and monitor the subsequent execution timeline and location announcements for the new diagnostic centres.
Chandan Healthcare Gets Shareholder Approval to Divest 100% Stake in Chandan Pharmacy
Chandan Healthcare Limited announced that its shareholders have approved a special resolution for the complete disinvestment of its shareholding in material subsidiary Chandan Pharmacy Limited. In the EGM held on August 29, 2026, the resolution received 99.90% approval of the 46.52 lakh total valid votes cast. Promoter group votes of 23.56 lakh were treated as invalid/abstained due to interested party status. The transaction will formalize the company's exit from the pharmacy retail arm to focus on diagnostic operations.
Confidence: HIGH
What changedShareholders formally approved the exit and complete stake sale in material subsidiary Chandan Pharmacy Limited.
Why it mattersThe sale allows the company to exit retail pharmacy operations and redeploy resources and management bandwidth toward core diagnostic lab expansion and high-margin super-specialty testing.
Resolution approval rate: 99.90%Total valid votes: 46,52,230Votes polled: 70,07,810Voting turnout: 28.66%Stake to be disinvested: 100% (entire shareholding)
📅 Short termShare price reaction will depend on upcoming details regarding transaction valuation and timeline of cash receipt.
📈 Long termStreamlines operations to focus purely on diagnostic and pathology networks, reducing exposure to competitive retail pharmacy margins.
⚠ Risk flags
- Transaction valuation and counterparty details not disclosed in filing
- Promoter group marked as interested in the transaction
Key Highlights
Special resolution passed to divest 100% shareholding in material subsidiary Chandan Pharmacy Limited
99.90% of total valid votes (46,47,430 votes) cast in favour of the disinvestment
Total 70,07,810 votes polled across 52 voters, representing 28.66% of total 2,44,52,064 outstanding shares
Promoter group's 23,55,580 votes categorized as invalid/abstained due to interested party status
👀 What to Watch
Track subsequent disclosures for the transaction consideration value, buyer identity, closing timeline, and capital allocation plan for the divestment proceeds.
Chandan Healthcare EGM discusses ₹16.77 Cr divestment of 53.56% stake in Chandan Pharmacy
Chandan Healthcare Limited conducted an Extra Ordinary General Meeting on August 29, 2026, seeking shareholder approval to sell its entire 53.56% stake in subsidiary Chandan Pharmacy Limited (CPL). The stake is being sold to group company Chandan Hospital Limited for a total consideration of approximately ₹16.77 crore. The transaction valuation is based on an independent valuation report dated August 3, 2026. Proceeds from the divestment will be redeployed into capital expenditure and organic expansion of the company's core diagnostic business.
Confidence: HIGH
What changedChandan Healthcare has completed the EGM proceedings to sell its complete 53.56% stake in Chandan Pharmacy to group company Chandan Hospital for ₹16.77 crore.
Why it mattersThe sale allows Chandan Healthcare to exit the lower-margin retail medicine distribution segment and redirect ₹16.77 crore in capital toward high-growth, high-margin diagnostic lab expansions.
Disinvestment consideration: ₹16.77 croreStake being sold: 53.56%Valuation report date: 03 August 2026Post-deal holding in CPL: Nil
📅 Short termScrutinizer's voting results will confirm formal passage of the special resolution in the coming days.
📈 Long termExiting non-core pharmacy operations sharpens corporate focus purely on diagnostics and provides non-dilutive capital to fund network expansion.
⚠ Risk flags
- Related-party transaction: sale is to group company Chandan Hospital Limited
- Loss of consolidated revenue previously contributed by the pharmacy subsidiary
Key Highlights
Divestment of entire 53.56% equity stake in subsidiary Chandan Pharmacy Limited
Total transaction consideration of approximately ₹16.77 crore
Buyer is group entity Chandan Hospital Limited, based on independent valuation dated August 3, 2026
Proceeds earmarked for organic expansion and capex in core diagnostic operations
Special resolution put to shareholder remote e-voting and e-voting at the EGM
👀 What to Watch
Track the upcoming disclosure of the scrutinizer's report for formal voting results, followed by the closing timeline and deployment of the ₹16.77 crore proceeds into diagnostic expansion.
Chandan Healthcare Targets 1,000 Franchises in FY27; Divests Pharmacy Stake for ₹16.77 Cr
Chandan Healthcare reported strong expansion momentum in its Q1 FY27 earnings call, expanding its network to 327 centers and accelerating its target to reach 1,000 franchise centers within this financial year. In Q1, B2B revenue grew 94% YoY, while B2C and B2G rose 20% and 22% YoY respectively. The company also announced the divestment of its 53.56% stake in Chandan Pharmacy Limited for ₹16.77 crore to refocus capital entirely onto high-margin diagnostics. Additionally, its partnership with Jeena Sikho achieved a monthly run-rate of ₹1.45 crore, covering 80% of partner facilities.
Confidence: HIGH
What changedSubmission of the detailed Q1 FY27 earnings call transcript detailing rapid franchise scaling, divestment of non-core pharmacy operations, and multi-state expansion plans.
Why it mattersExiting lower-margin pharmacy trading to reallocate ₹16.77 crore into higher-margin (~65% gross margin) franchise diagnostics enhances return metrics and accelerates geographic scaling under 'One District One Lab'.
Pharmacy Stake Divestment Value: ₹16.77 crFranchise Center Target (FY27): 1,000 centersJeena Sikho Monthly Run-rate: ₹1.45 crB2B Revenue Growth YoY: 94%Average Franchise Business Margin: nearly 65%
📅 Short termSentiment is supported by robust growth across B2B/B2C verticals and the redeployment of ₹16.77 crore cash proceeds into fast-turnaround diagnostic centers.
📈 Long termAsset-light franchise scaling toward 1,000 locations coupled with high-end modalities (PET scans, genome lab) provides operational leverage and strengthens regional market share across North India.
⚠ Risk flags
- Intense regional price competition in diagnostic franchise models from organized players.
- Execution risks in scaling from 375 to 1,000 franchise centers within a single fiscal year.
Key Highlights
Franchise target accelerated to 1,000 centers in FY27 from earlier 3-year timeline, reaching 375 franchises to date with ~65% margin profile.
B2B business grew 94% YoY, B2C grew 20% YoY, and B2G grew 22% YoY in Q1 FY27.
Divested entire 53.56% stake in Chandan Pharmacy for ₹16.77 crore to redeploy capital into core diagnostic expansion.
Jeena Sikho strategic partnership monthly diagnostic revenue crossed ₹1.45 crore, currently operational across ~80% partner centers.
Upcoming pipeline includes 8 comprehensive diagnostic centers and 2 PET scan machines operational within 2-4 months.
👀 What to Watch
Track the quarterly pace of franchise additions toward the 1,000-center target, operationalization of the 8 comprehensive diagnostic centers, and EBITDA margin expansion post pharmacy divestment.
Chandan Healthcare Approves Q1 Results; Deploys ₹11.20 Cr Towards Business Expansion
Chandan Healthcare Limited's Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also reviewed the utilization of its ₹104.13 Cr preferential share warrant issue, confirming zero deviation from stated objects. During the quarter, ₹11.20 Cr was deployed towards business expansion, bringing total utilization to date to ₹28.13 Cr. The company is yet to receive ₹70.20 Cr against outstanding warrants, receivable upon conversion by July 28, 2027.
Confidence: HIGH
What changedThe Board has formally approved Q1 FY27 results and reported progress on warrant fund deployments with ₹11.20 Cr spent in Q1.
Why it mattersDemonstrates continuous capital deployment towards diagnostic network expansion, while confirming warrant proceeds are being utilized without deviations from offer objects.
Total Preferential Warrant Issue Size: ₹104.13 CrWarrant Funds Receivable Upon Conversion: ₹70.20 CrFunds Utilized in Q1: ₹11.20 CrTotal Cumulative Funds Utilized: ₹28.13 CrWarrant Conversion Deadline: July 28, 2027
📅 Short termTrading window reopens 48 hours post-declaration. Market reaction will hinge on underlying margin and revenue growth figures from the Q1 financial statements.
📈 Long termOngoing deployment of growth capital into network expansion and upcoming ₹50 Cr acquisitions support the company's 20-25% target growth trajectory.
⚠ Risk flags
- Potential dilution risk upon conversion of share warrants into equity by July 2027
- Acquisition allocation of ₹50 Cr remains unutilized and pending deal execution
Key Highlights
Board approved unaudited Standalone and Consolidated financial results for the quarter ended June 30, 2026
Reviewed ₹104.13 Cr preferential warrant fundraise allocated to Acquisitions (₹50 Cr), Expansion (₹44.5 Cr), and GCP (₹9.63 Cr)
₹11.20 Cr utilized during the quarter ended June 30, 2026, specifically towards business expansion and vendor settlements
₹70.20 Cr out of the ₹104.13 Cr warrant issue remains receivable upon conversion by July 28, 2027
Unutilized proceeds of ₹5.80 Cr are maintained in fixed deposits (yielding 6.5% p.a.) and ICICI bank accounts
👀 What to Watch
Track the detailed P&L metrics once fully parsed, alongside the deployment of the remaining ₹50 Cr allocated for acquisitions and conversion of warrants before July 2027.
Rs 16.77 Cr Divestment: Chandan Healthcare to Sell 53.56% Stake in Pharmacy Subsidiary
Chandan Healthcare is divesting its entire 53.56% stake in Chandan Pharmacy Limited (CPL) to a group company, Chandan Hospital Limited, for a consideration of Rs 16.77 cr. The transaction, based on an independent valuation of Rs 31.31 cr, aims to exit the low-margin pharmacy segment which reported a 5.28% EBITDA margin in FY26. The company plans to redeploy the proceeds into its core diagnostics business, which boasts a significantly higher EBITDA margin of 31.45%. This move is expected to be margin-accretive at the consolidated level and simplify the corporate structure for better investor benchmarking.
Confidence: HIGH
What changedChandan Healthcare is exiting the pharmacy business by selling its majority stake to a related party, resulting in CPL ceasing to be a subsidiary.
Why it mattersThe divestment removes a low-margin, capital-intensive drag on the consolidated financials, allowing the company to focus entirely on its high-margin diagnostics business and providing liquidity for expansion.
Divestment Consideration: Rs 16.77 crStake Sold: 53.56%Pharmacy EBITDA Margin (FY26): 5.28%Diagnostics EBITDA Margin (FY26): 31.45%Consideration vs FY26 Standalone Revenue: 10.43%
📅 Short termThe market is likely to react positively to the news of capital recycling and the focus on a higher-margin pure-play diagnostics model.
📈 Long termStructurally positive as it improves the return profile of the company by reallocating capital from a 5% EBITDA business to a 30%+ EBITDA business.
⚠ Risk flags
- Related-party transaction with a group company
- Execution risk in redeploying proceeds effectively into new centers
Key Highlights
Divestment of 1,72,992 equity shares representing a 53.56% stake in Chandan Pharmacy Limited
Transaction consideration of Rs 16.77 cr based on an independent valuation of Rs 31.31 cr as of August 3, 2026
Exit from a low-margin business where over 70% of revenue was derived from B2B supply to group hospitals
Diagnostics core EBITDA margin of 31.45% in FY26 vs. Pharmacy EBITDA margin of 5.28%
Proceeds to be utilized for the development of new diagnostic centers to drive higher-margin growth
👀 What to Watch
Watch for the completion timeline of the divestment and the subsequent quarterly reporting to verify the expected expansion in consolidated EBITDA margins and the pace of new diagnostic center roll-outs.
Rs 16.77 Cr Divestment of Pharmacy Stake to Focus on High-Margin Diagnostics
Chandan Healthcare is divesting its entire 53.56% stake in Chandan Pharmacy Limited (CPL) to a group company, Chandan Hospital Limited, for Rs 16.77 crore. This strategic exit from the low-margin pharmacy business (5.28% EBITDA margin in FY26) allows the company to focus entirely on its high-margin diagnostics core (31.45% EBITDA margin). The transaction is based on an independent valuation of Rs 31.31 crore for CPL. Management intends to redeploy the proceeds into expanding the diagnostic center network to drive higher consolidated profitability.
Confidence: HIGH
What changedChandan Healthcare is transitioning from a diversified healthcare provider to a pure-play diagnostics entity by fully exiting its pharmacy subsidiary.
Why it mattersThe pharmacy business was margin-dilutive and capital-intensive; removing it simplifies the corporate structure and allows capital to be concentrated in the 30%+ EBITDA margin diagnostics segment, potentially leading to a valuation re-rating.
Divestment Consideration: Rs 16,77,10,554.24Stake Divested: 53.56%Diagnostics EBITDA Margin (FY26): 31.45%Pharmacy EBITDA Margin (FY26): 5.28%Pharmacy Revenue (FY26): Rs 120.64 crDiagnostics Revenue (FY26): Rs 160.77 cr
📅 Short termThe market is likely to react positively to the cash infusion and the strategic focus on higher-margin operations, which should immediately improve the consolidated financial profile.
📈 Long termStructural shift toward a high-ROCE diagnostics model; the successful redeployment of capital into new centers will be the primary driver of long-term value creation.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Related-party transaction (sale to a group company)
- Significant reduction in consolidated revenue scale due to pharmacy exit
Key Highlights
Divestment of 1,72,992 equity shares (53.56% stake) in Chandan Pharmacy Limited for Rs 16.77 crore.
Exiting a segment with a low EBITDA margin of 5.28% compared to the core diagnostics margin of 31.45% in FY26.
Pharmacy business was heavily reliant on group entities, with over 70% of revenue coming from B2B supply to Chandan Hospital Limited.
Transaction based on an independent valuation report dated August 3, 2026, valuing the pharmacy entity at Rs 31.31 crore.
Proceeds will be utilized to fund the development of new diagnostic centers to support a 20-25% growth target.
👀 What to Watch
Monitor the timeline for the deployment of the Rs 16.77 crore into new diagnostic centers and observe the expected expansion in consolidated EBITDA margins in the first full quarter post-divestment.
Rs 16.77 Cr Divestment: Chandan Healthcare to Sell 53.56% Stake in Pharmacy Subsidiary
Chandan Healthcare is divesting its entire 53.56% stake (1,72,992 shares) in Chandan Pharmacy Limited (CPL) to group company Chandan Hospital Limited for Rs 16.77 crore. The transaction is based on an independent valuation of Rs 31.31 crore for the pharmacy business as of August 3, 2026. This strategic exit from the low-margin pharmacy segment, where 70% of revenue was B2B-heavy, aims to refocus management and capital on the higher-margin diagnostics core. Proceeds will be redeployed to fund the expansion of new diagnostic centers, supporting the company's 20-25% growth target.
Confidence: HIGH
What changedChandan Healthcare has exited the pharmacy business entirely, transitioning from a diversified healthcare provider to a focused diagnostics-led entity.
Why it mattersThe pharmacy business was diluting overall margins due to its B2B-heavy mix; exiting it provides immediate capital for higher-growth diagnostic expansion and simplifies the corporate structure for better market benchmarking.
Stake Divested: 53.56%Consideration Received: Rs 16,77,10,554.24Total Subsidiary Valuation: Rs 31,31,36,168Subsidiary B2B Revenue Mix: >70%Valuation Date: August 3, 2026
📅 Short termThe market is likely to view the capital infusion and margin-accretive restructuring positively, potentially improving sentiment toward the stock in the coming weeks.
📈 Long termStructural shift to a pure-play diagnostics model should lead to sustained margin expansion and may support a valuation re-rating as the company aligns with higher-multiple diagnostic peers.
⚠ Risk flags
- Related-party transaction (sale to a group company)
- Execution risk in redeploying capital effectively into new diagnostic centers
Key Highlights
Divestment of entire 53.56% stake (1,72,992 equity shares) in Chandan Pharmacy Limited
Cash consideration of Rs 16,77,10,554 based on a total business valuation of Rs 31.31 crore
Exit from a segment where over 70% of revenue was derived from low-margin B2B supply to group hospitals
Proceeds to be fully redeployed into developing new diagnostic centers to drive higher EBITDA
Independent valuation conducted by Registered Valuer Gaurang Gaurav on August 3, 2026
👀 What to Watch
Monitor the timeline for the redeployment of the Rs 16.77 crore proceeds into new diagnostic centers and observe the impact on consolidated EBITDA margins in the next two quarters.
Rs 16.77 Cr Disinvestment of Chandan Pharmacy Limited Subsidiary
Chandan Healthcare Limited has called an Extraordinary General Meeting (EGM) on August 29, 2026, to seek shareholder approval for the sale of its entire 53.56% stake in Chandan Pharmacy Limited. The stake, comprising 1,72,992 shares, will be sold to a related party, Chandan Hospital Limited, for a total consideration of Rs 16.77 crore. The valuation is set at Rs 969.47 per share, with payments structured in three tranches ending in September 2027. The company will earn 10% annual interest on the deferred portion of the sale proceeds.
Confidence: HIGH
What changedThe company is transitioning from a majority owner of its pharmacy business to a complete exit, selling the stake to a related party hospital entity.
Why it mattersThis is a material divestment of a subsidiary. While it provides a clear exit valuation and cash for redeployment, the deferred payment structure and related-party nature of the buyer require scrutiny regarding capital allocation efficiency.
Stake being sold: 53.56%Total Consideration: Rs 16,77,10,554.24Fair Value per share: Rs 969.47Interest on deferred payment: 10% p.a.Final payment deadline: September 1, 2027
📅 Short termThe stock may see volatility as investors digest the valuation of the pharmacy business and the impact of the related-party transaction.
📈 Long termThe divestment suggests a strategic focus on the core diagnostic and super-specialty testing business; long-term value depends on how effectively the Rs 16.77 cr is reinvested.
⚠ Risk flags
- Related-party transaction (sale to Chandan Hospital Limited)
- Deferred payment risk (50% of consideration due only in late 2027)
- Loss of revenue contribution from a material subsidiary
Key Highlights
Divestment of 1,72,992 equity shares representing 53.56% of the paid-up capital of Chandan Pharmacy Limited
Total principal consideration fixed at Rs 16,77,10,554.24 based on an independent fair value of Rs 969.47 per share
Payment schedule: 25% by Sept 1, 2026; 25% by March 1, 2027; and the remaining 50% by Sept 1, 2027
Interest at 10% per annum will accrue on the outstanding principal from September 1, 2026
Chandan Pharmacy Limited will cease to be a subsidiary of the company upon completion of the transfer
👀 What to Watch
Investors should monitor the EGM voting results on August 29, 2026, and evaluate the impact of losing pharmacy revenue against the cash inflow of Rs 16.77 crore intended for core diagnostic expansion.
₹16.77 Cr Disinvestment: Chandan Healthcare to sell 53.56% stake in Chandan Pharmacy Ltd
Chandan Healthcare has approved the sale of its entire 53.56% stake in Chandan Pharmacy Limited to a related party, Chandan Hospital Limited, for ₹16.77 crore. The subsidiary is a major revenue driver, contributing ₹120.22 crore (42.94%) to consolidated FY26 revenue, though it only accounts for 6.63% of consolidated net worth. The consideration will be paid in three tranches ending September 2027, with a 10% annual interest rate on deferred payments. A special resolution for shareholder approval is set for August 29, 2026.
Confidence: HIGH
What changedChandan Healthcare is exiting its pharmacy subsidiary, transitioning from a consolidated diagnostic-and-pharmacy model to a diagnostic-focused entity.
Why it mattersThe transaction removes a high-revenue but relatively low-net-worth subsidiary from the consolidated books, providing ₹16.77 Cr in liquidity but significantly reducing the reported top-line.
Sale Consideration: ₹16.77 CrSubsidiary Revenue Contribution: 42.94%Subsidiary Net Worth Contribution: 6.63%Valuation per share: ₹969.47Interest on deferred payment: 10% p.a.
📅 Short termThe market may react to the sharp drop in consolidated revenue, though the cash inflow and interest income provide a liquidity cushion.
📈 Long termThe company is narrowing its focus to core diagnostics; long-term value depends on whether diagnostic margins can compensate for the loss of the pharmacy business scale.
⚠ Risk flags
- Related-party transaction
- Significant reduction in consolidated revenue (43%)
- Credit risk associated with deferred payment tranches until Sept 2027
Key Highlights
Divestment of 1,72,992 equity shares representing 53.56% of Chandan Pharmacy Limited.
Chandan Pharmacy contributed 42.94% (₹120.22 Cr) of the group's ₹280 Cr consolidated revenue in FY26.
Total consideration of ₹16.77 Cr based on an independent valuation of ₹969.47 per share.
Payment schedule: 25% by Sept 2026, 25% by March 2027, and 50% by Sept 2027.
Deferred payments to earn 10% interest per annum starting September 1, 2026.
👀 What to Watch
Investors should monitor the EGM results on August 29, 2026, and watch for management commentary on how they intend to replace the 43% revenue contribution lost from this divestment.
Chandan Healthcare: Withdrawal of Financial Irregularity Complaints by Dayal Institute
Dayal Institute of Medical Sciences Limited has withdrawn its complaint dated May 18, 2026, against Chandan Healthcare Limited and its promoters. The complaint, which alleged financial irregularities, had been filed with the ROC, SEBI, NSE, and the Economic Offences Wing of the UP Police. Both parties reached an amicable settlement following a reconciliation of accounts and balance confirmation. The company expects this resolution to remove previous uncertainties with no adverse impact on its financial position.
Confidence: HIGH
What changedA formal complaint alleging financial irregularities against the company and its promoters has been settled and withdrawn by the complainant.
Why it mattersThis removes a significant regulatory and legal overhang that could have led to forensic audits or penalties, potentially restoring confidence in the company's corporate governance.
Original Complaint Date: 18th May, 2026Settlement Date: 31st July, 2026Related Party Transaction (Annual): ₹5-6 crExpected Growth Rate: 20-25%
📅 Short termThe stock may see a positive reaction as the immediate threat of regulatory action or police investigation into financial irregularities is mitigated.
📈 Long termIf the settlement is final and no further irregularities are found by regulators, the company can focus on its pan-India expansion and strategic partnership with Jeena Sikho.
⚠ Risk flags
- Residual regulatory scrutiny from SEBI/ROC despite complainant withdrawal
- Lack of disclosure on specific settlement terms or financial payouts
Key Highlights
Complaint dated May 18, 2026, alleging financial irregularities has been withdrawn in its entirety.
Amicable settlement reached with Dayal Institute of Medical Sciences Limited (formerly Chandan Institute).
Withdrawal covers filings with the Registrar of Companies (ROC), SEBI, NSE, and the Economic Offences Wing (EOW).
Settlement was finalized on July 31, 2026, following balance confirmation and account reconciliation.
Company confirms the settlement removes uncertainty regarding earlier allegations against promoters and directors.
👀 What to Watch
Investors should monitor if regulatory bodies like SEBI or ROC close their files or continue independent inquiries. Check upcoming quarterly results for any one-time settlement costs or legal expenses related to this dispute.
